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Management of patient with jaundice  
General Outcome 
The students should be able to describe main links of pathogenesis, 
clinical features, diagnostic and treatment of jaundice. 
 
The aim of this topic is to provide the student with an opportunity to: 
 Provide a basic overview of the pathophysiology, diagnosis, and 
classification of jaundice.  
 Evaluate guideline-based management strategies for the treatment 
of jaundice.  
 Develop an individualized pharmacotherapy and monitoring plan 
for the management of jaundice, when given specific patient information.  
 
Specific Learning Outcomes:  
Upon successful completion of this unit, the students should be able to:  
1. Describe the jaundice classifications.  
2. Describe the main mechanism of etiopathogenesis.  
3. Describe the main clinical features of jaundice. 
4. List and describe the group of drugs that are used in the treatment 
of jaundice and give specific examples of each. 
5. Make a treatment plan the jaundiced patient. 
 
Specification of the theoretical question for training of "Manage-
ment of the jaundiced patient"  
Student must know:  
1. What is the definition of jaundice?  
2. What are the main causes of jaundice?  
3. What are the main pathogenetic links of jaundice?  
4. What are the main types of jaundice?  
5. What laboratory tests are used in the jaundiced patient? 
6. What imaging studies are used in the jaundiced patient?  
7. What treatment methods are used in the jaundiced patient? 
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Jaundice is not a diagnosis per se but rather a physical manifestation 
of elevated serum bilirubin. It is not a common chief complaint. Instead, the 
jaundiced patient often presents with a related symptom, (e.g., abdominal 
pain, pruritis, vomiting, or substance ingestion). Hyperbilirubinemia is only 
dangerous in and of itself in neonates, where it can cross the blood brain 
barrier and deposit in the brain tissue, causing encephalopathy (kernicterus). 
In adults, jaundice serves as a marker for potentially serious hematologic or 
hepatobiliary dysfunction such as massive hemolysis, fulminant hepatic 
failure, or ascending cholangitis. Indeed, these are the cases where the emer-
gency physician must intervene aggressively in order to maximize good out-
comes. Fortunately, the majority of jaundiced patients have a more indolent 
course and the emergency physician serves as a facilitator in the diagnostic 
work-up, initiating management and ensuring that an appropriate disposition 
is made. Whether jaundice is the presenting complaint or an incidental phy-
sical finding, it requires the physician to be an astute diagnostician. Because 
the differential is so broad, a thorough history and physical examination 
must be performed – a challenge in even a moderately busy department. 
The history and physical examination will help narrow the differential diag-
noses, driving the work-up and disposition. The clinical pathway provided 
can be used as a quick reference to help facilitate caring for these patients.  
Etiology and pathophysiology 
Jaundice is the physical manifestation of elevated serum bilirubin. 
The normal serum concentration of bilirubin is less than 1 mg/dL (17 μmol/L). 
Typically, jaundice is not detectable clinically until serum bilirubin reaches 
2.5 mg/dL. It is first seen in the conjunctiva or oral mucous membranes 
such as the hard palate or under the tongue. As the serum concentration of bi-
lirubin rises, jaundice proceeds caudally. Encephalopathy becomes a concern 
at levels of 20–25 mg/dL. Comprehending normal bilirubin metabolism is 
crucial to understanding the pathologic conditions that cause jaundice. Bili-
rubin is derived from the breakdown of heme molecules; the majority (80 %) 
is from senescent red blood cells (RBCs). The remaining 20 % comes from 
other heme-containing proteins. The reticuloendothelial cells of the liver 
and spleen destroy the RBCs, releasing unconjugated bilirubin into the circu-
lation. While in circulation, bilirubin is bound to albumin and enters hepato-
cytes passively, where it undergoes glucuronidation by a family of enzymes 
called uridinediphospho-glucuronosyltransferases (UGT). The conjugated 
bilirubin molecules are actively transported across the canalicular memb-
ranes into the biliary system. This is detailed in figure.  
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Bilirubin conjugation 
 
Bilirubin is stored as part of bile in the gallbladder and emptied into 
the duodenum. In the colon, the majority is metabolized to stercobilin or 
urobilinogen by colonic bacteria. Stercobilin is excreted in the stool. Urobi-
linogen is reabsorbed into the bloodstream and excreted in the urine. The re-
mainder of conjugated bilirubin in the gut is de-conjugated and taken up by 
intestinal epithelial cells. From there, it enters the portal circulation and 
returns to the liver (enterohepatic circulation). Conjugated bilirubin can also 
enter circulation from diffusion out of the hepatocytes. Once in circulation, 
it is filtered by the glomerulus and then reabsorbed so that no direct bili-
rubin is excreted under normal conditions. When the filtered load of direct 
bilirubin exceeds the tubular absorptive capacity, direct bilirubin appears 
in the urine. Thus glomerular filtration plays a role in determining serum levels 
of direct bilirubin, and patients who have both liver disease and renal insuf-
ficiency can have extraordinarily high bilirubin levels. In the laboratory, 
conjugated bilirubin is the fraction that reacts directly with the reagents. 
Thus it is reported as "direct" bilirubin. The unconjugated fraction requires 
the addition of an accelerator compound and is referred to as "indirect" bili-
rubin. There is an extensive differential diagnosis for hyperbilirubinemia 
that is initially narrowed by identifying the fraction of bilirubin that is 
elevated (direct versus indirect). For primarily direct hyperbilirubinemia, 
potential causes are further divided into cholestatic versus hepatocellular 
injury patterns based on the liver function tests. 
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Conditions causing indirect hyperbilirubinemia 
There are three basic pathophysiologic mechanisms that lead to 
indirect hyperbilirubinemia: overproduction of bilirubin, impaired bilirubin 
uptake, and impaired conjugation. Causes of indirect hyperbilirubinemia are 
presented in table 1. 
 
Table 1  
Causes of indirect hyperbilirubinemia 
Increased bilirubin production Hemolysis (intravascular or extravascular) 
Impaired RBC synthesis (megaloblastic, 
sideroblastic, iron deficiency anemia, lead 
poisoning) 
Impaired hepatic 
bilirubin uptake 
Congestive heart failure 
Portosystemic shunts 
Drugs (rifampin, probenecid) 
Impaired bilirubin conjugation Crigler-Najjar syndrome 
Gilbert's syndrome 
Neonates 
Hyperthyroidism 
Ethinyl estradiol 
Liver diseases (chronic persistent hepatitis, 
advanced cirrhosis, Wilson's disease) 
 
Overproduction of bilirubin 
Overproduction of bilirubin is due to decreased synthesis or increased 
destruction (hemolysis) of RBCs. The differential diagnosis for hemolytic 
anemia is listed in table 2. Decreased RBC synthesis occurs in various ane-
mias (iron deficiency, megaloblastic, and sideroblastic) and lead poisoning. 
In these conditions, the reticuloendothelial cells of the bone marrow degrade 
heme molecules that are not incorporated into RBCs. 
Impaired bilirubin uptake 
Conditions that cause decreased hepatic circulation, such as congestive 
heart failure or portosystemic shunts, can lead to decreased bilirubin uptake 
in the sinusoids. Cirrhosis, Gilbert’s syndrome, and drugs such as rifampin 
or probenecid can have the same effect.  
Impaired conjugation 
Impaired conjugation results from impaired or absent UGT in the he-
patocytes. Inherited causes for this include Gilbert's syndrome and Crigler-
Najjar syndrome. Acquired causes include hormonal modulation (hyperthy-
roidism and ethinyl estradiol), antibiotics (gentamycin, novobiocin), and liver 
disease (chronic hepatitis, cirrhosis, and Wilson's disease). 
Conditions causing direct hyperbilirubinemia 
There are multiple acquired and inherited causes for direct hyperbiliru-
binemia. The most familiar causes are the Dubin-Johnson and Rotor syndromes. 
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Table 2 
Causes of hemolysis 
Congenital Hereditary spherocytosis 
Glucose-6-phosphate dehydrogenase 
deficiency (G6PD) 
Sickle cell disease 
Acquired Autoimmune 
Cold and warm agglutinins 
Drug-induced 
Microangiopathic hemolytic anemia (MAHA), 
disseminated intravascular coagulation (DIC), 
thrombotic thrombocytopenic purpura (TTP),  
hemolytic uremic syndrome (HUS) 
Paroxysmal nocturnal hemoglobinuria (PNH) 
Mechanical valve 
 
The former affects the biliary excretion of organic anions while the latter 
is a disorder of hepatic storage of bilirubin. Both are benign syndromes that 
have fluctuating elevations of both conjugated and unconjugated hyperbilirubi-
nemia. Additionally, there are other conditions, progressive familial intrahepatic 
cholestasis, and benign recurrent intrahepatic cholestasis that cause a conjugated 
hyperbilirubinemia as a result of reduced bile flow. Acquired conditions can 
be divided into biliary obstruction, intrahepatic cholestasis, and hepatocellular 
injury. Both inherited and acquired causes are summarized in table 3. 
 
Table 3 
Causes of direct hyperbilirubinemia 
Extrahepatic cholestasis  
(biliary obstruction) 
Choledocholithiasis 
Intrinsic and extrinsic tumors 
Primary sclerosing cholangitis 
AIDS cholangiopathy 
Acute or chronic pancreatitis 
Strictures 
Parasitic infections 
Intrahepatic cholestasis Viral hepatitis 
Alcoholic hepatitis 
Non-alcoholic steatohepatitis 
Primary biliary cirrhosis 
Drugs and toxins 
Sepsis/hypoperfusion 
Infiltrative diseases 
Total parenteral nutrition 
Pregnancy 
Cirrhosis 
Hepatocellular injury See table 7 
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Extrahepatic biliary obstruction 
Extrahepatic biliary obstruction can lead to both a conjugated and 
unconjugated hyperbilirubinemia. As conjugated bilirubin increases in the he-
patocytes, glucuronidation is reversed and some of the unconjugated bilirubin 
leaks into the plasma. Alkaline phosphatase (AP) and gamma-glutammyl-
transferase (GGT) are also elevated due to dilated biliary ducts. The diffe-
rential diagnosis is provided in table 4 and includes cholelithiasis, tumors, 
infectious causes, pancreatitis, primary sclerosing cholangitis, and strictures. 
Gallstones can directly or indirectly obstruct extrahepatic bile ducts; an example 
is the Mirizzi syndrome where an impacted cystic duct stone causes gall-
bladder distension and leads to hepatic duct compression. Both intrinsic and 
extrinsic tumors can lead to extrahepatic cholestasis. Common causes are 
pancreatic carcinoma, hepatocellular carcinoma (HCC), cholangiocarcinoma, 
and metastatic disease. Infectious causes can include ascending cholangitis, 
parasitic infections, and AIDS cholangiopathy. Parasites include Ascaris 
lumbricoides (which migrates into the bile ducts from the intestines) and 
liver flukes (such as Clonorchis sinensis which lay eggs in the smaller bile 
ducts). Cryptosporidium, cytomegalovirus, and HIV most commonly cause 
AIDS cholangiopathy. 
 
Table 4 
Causes of extrahepatic cholestasis 
Tumors Cholangiocarcinoma 
Pancreatic carcinoma 
Periampullary carcinoma 
Metastatic disease 
Infection AIDS cholangiopathy 
cytomegalovirus (CMV), 
Cryptosporidium spp, HIV 
Parasitic infection 
Ascaris lumbricoides 
Cholangiopathy Choledocholithiasis 
Biliary stricture 
Primary sclerosing cholangitis 
Sphincter of Oddi dysfunction 
Pancreatitis Acute or chronic 
 
Intrahepatic cholestasis 
There are a number of conditions that lead to intrahepatic cholestasis 
either primarily or as a result of hepatocellular injury. Please refer to Table 5 
for a complete list. These patients usually present in a similar fashion to 
extrahepatic obstruction but have patent bile ducts. 
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Table 5  
Causes of intrahepatic cholestasis 
Acute hepatocellular injury Viral hepatitis 
Alcoholic fatty liver/hepatitis 
Non-alcoholic steatohepatitis 
Chronic hepatocellular  
injury 
Primary sclerosing cholangitis 
Primary biliary cirrhosis 
Drugs 
Hepatitis 
Cirrhosis 
Multifactorial Total parenteral nutrition 
Systemic infection 
Postoperative 
Sickle cell disease/crisis 
Organ transplantation (rejection, graft 
vs. host, venoocclusive disease 
Miscellaneous Hypotension/hypoxemia/congestive 
heart failure (CHF) 
Budd-Chiari syndrome 
Parasitic infection 
Inherited/endocrine Benign recurrent cholestasis 
Pregnancy 
Thyrotoxicosis 
Infiltrative/granulomatous Amyloidosis 
Lymphoma 
Sarcoidosis 
Tuberculosis 
 
Hepatocellular injury 
A list of conditions causing hepatocellular injury is provided in Table 6. 
There is considerable overlap between these conditions and those that cause 
intrahepatic cholestasis. This is due to the variable presentation and natural 
progression of many of these diseases. The primary mechanism can be distin-
guished based on the level of elevation of the various hepatic markers. Ele-
vation of transaminases relative to bilirubin and alkaline phosphatase favors 
a hepatocellular injury pattern whereas elevation of bilirubin and alkaline 
phosphatase relative to transaminases favors a cholestatic picture. Toxic doses 
of APAP cause hepatic necrosis by overwhelming the usual metabolic 
pathways of glucuronidation and sulfation. When this happens, the primary 
route of metabolism becomes oxidation by cytochrome P450. This produces 
the reactive electrophilic molecule N-acetyl-p-benzoquinoneimine (NAPQI). 
Under normal conditions, the free radicals from this species are scavenged 
by glutathione. In massive overdoses, the glutathione reserves are depleted 
leading to oxidative damage to the hepatocytes. 
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Table 6 
Differential diagnosis of hepatocellular jaundice 
Neoplasms Hepatocellular carcinoma 
Cholangiocarcinoma 
Metastatic disease 
(gastrointestinal, genitourinary, bronchogenic) 
Hereditary Wilson's disease 
Alpha-1-antitrypsin deficiency 
Hemochromatosis 
Miscellaneous Secondary biliary cirrhosis 
Cryptogenic cirrhosis 
Infections - viral Hepatitis viruses (A-E) 
Herpes viruses (CMV, HSV) 
Hemorrhagic viruses (Ebola, Marburg, 
Lassa, yellow fever) 
Adenovirus, enterovirus 
Infections – bacterial Tuberculosis (TB) 
Leptospirosis 
Syphilis 
Abscesses 
Brucellosis 
Rickettsia 
Whipple's disease 
Infections – fungal Candida 
Blastomyces 
Cocciodies 
Histoplasmosis 
Cryptococcus 
Infections – parasitic Helminths – ascaris, clonorchis, 
schistosomiasis, echinococcus 
Protozoa – amebiasis, plasmodia, 
babesiosis, toxoplasmosis, leishmaniasis 
Toxic Medications 
Alcohol 
Chlorinated hydrocarbons 
Amanita phalloides toxin 
Aflatoxin 
Vitamin A1 
Arsenic 
Pyrrolizidine alkaloids 
Immunologic Autoimmune hepatitis 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Nonalcoholic steatohepatitis 
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Differential diagnosis 
The differential diagnosis of jaundice is broad, and a precise diagnosis 
is not always possible. For this reason, the EP has two primary responsibi-
lities: to identify and stabilize patients with life-threatening causes of jaundice 
(table 8) and to provide an appropriate work-up for non-emergent cases. 
The critical and emergent causes of jaundice include massive hemolysis, 
acute cholangitis, fulminant liver failure, acute fatty liver of pregnancy, and 
neonatal hyperbilirubinemia. Clues to a potentially critical patient with 
jaundice include altered mental status, fever, abdominal pain, bleeding, or hypo-
tension. A patient with the triad of jaundice, right upper quadrant (RUQ) 
pain, and fever has acute cholangitis until proven otherwise. This collection 
of signs and symptoms is known as Charcot's triad and occurs in 50–75 % 
of patients with acute cholangitis. Patients with acute suppurative cholangitis 
may be septic with altered mental status and hypotension (Reynold's pentad). 
It is associated with increased morbidity and mortality. Bacteria can enter 
the biliary system through several mechanisms such as retrograde ascent 
from the duodenum, invasion from the portal venous system, or mechanical 
disruption from endoscopic retrograde cholangiopancreatography (ERCP) 
or percutaneous drainage. Stents and gallstones can also serve as a nidus 
of infection. E. coli, Klebsiella spp, Enterobacter spp, and Enterococcus spp 
are the most common bacteria. Anaerobes are fairly uncommon. A jaundiced 
patient with elevated transaminases, encephalopathy, and coagulopathy is con-
sidered to have acute liver failure (ALF). If encephalopathy develops within 
eight weeks of the onset of illness, the condition is referred to as fulminant 
hepatic failure, whereas patients who develop encephalopathy in 8–26 weeks 
are said to have sub-fulminant failure. These patients are typically very ill at 
presentation and require close monitoring while in the emergency depart-
ment. The mortality approaches 80 %.  
History 
A careful history and physical examination are essential in narrowing 
the differential diagnosis. A prospective series of 220 patients with jaundice 
and/or cholestasis found history and physical examination to be 86 % sensitive 
in identifying intrahepatic versus extrahepatic disease. In addition to jaundice, 
patients may also complain of pruritis or constitutional symptoms such as 
malaise, nausea, and anorexia as a result of the elevated serum bilirubin. 
Other complaints may include recent weight loss or increased abdominal girth 
from ascites. Important historical questions include time of onset, presence 
or absence of pain (quality, location, and radiation), fever, history of abdo-
minal surgeries, birth history for neonates, medication history (especially the 
amount and time acetaminophen was taken), herbal medications, social history 
(including alcohol consumption, HIV and hepatitis risk factors, drug use, 
exposure to toxic substances or mushrooms, travel history, work history, and 
recreational history), and family history (including history of inherited 
diseases of liver or hemolytic disorders) (table 7). 
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Table 7 
Historical factors 
History of present illness/review  
of symptoms 
Abdominal pain 
Nausea 
Fever 
Pruritis 
Weight loss/gain 
Approximate time and amount 
of medications 
taken in overdose 
Past medical  
history 
HIV history 
Liver disease 
Medications Prescription medications  
(statins, oral contraceptives) 
PRN medications (especially APAP) 
Herbal remedies 
Social history Alcohol use 
Drug use (mushrooms) 
Travel history 
Occupation (chemical exposures) 
Family history Liver disease 
Neoplasms 
 
A thorough history can point to specific clinical syndromes. Jaundice 
with abdominal pain is suggestive of an obstructive cause or significant hepatic 
inflammation. Fever or chills associated with right upper quadrant pain is sug-
gestive of acute cholangitis (Charcot's triad). Painless jaundice is classic for 
common duct obstruction due to a pancreatic head mass (table 8). 
 
Table 8 
Clinical syndromes suggested by history 
Historical features Suspected diagnosis 
Fever, jaundice, right  
upper quadrant pain 
Ascending cholangitis 
Painless jaundice +/-  
weight loss 
Biliary obstruction from pancreatic head 
malignancy 
Jaundice with abdominal pain Hepatic inflammation or biliary obstruction 
Physical examination 
The evaluation of any patient begins with careful consideration of 
the presenting vital signs. While they may not always help narrow the dif-
ferential diagnosis in a patient presenting with jaundice, they will aid in deter-
mining urgency of interventions and disposition. Fever can indicate global 
infection from sepsis and bacteremia, or more focal infection such as hepa-
titis, ascending cholangitis, and cholecystitis. Tachycardia, although non-
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specific, can indicate distress due to pain, fever, or anemia. Patients can be 
tachypneic and/or hypoxic as a result of pleural effusions in the case of end-
stage liver disease or pulmonary edema in sepsis-associated acute lung injury. 
Hypotension could also be a marker of sepsis, anemia due to hemolysis, or 
fluid shifts in end-stage liver disease and pancreatitis. A global assessment 
of the patient will also aid in the differential diagnosis and disposition. Note 
if the patient appears to be in distress due to dyspnea, hypoperfusion, or pain. 
Alterations in mental status are important to note as acute or chronic liver 
failure can present with hepatic encephalopathy. The skin examination is 
often used to estimate the level of serum bilirubin. However, jaundice is 
optimally seen in natural light, a rare commodity in most EDs, so it may be 
difficult to detect. Classic teaching is that jaundice first appears in the sclerae, 
conjunctiva, and hypoglossal regions and generally spreads cephalocaudally. 
Additionally, there are other factors that can affect the correlation between 
clinical jaundice and total body bilirubin content. Drugs such as salicylates 
or sulfonamides and free fatty acids can displace bilirubin from albumin, 
causing it to deposit in the tissues; this makes the clinical appreciation of jaun-
dice appear to be out of proportion from the laboratory measurement of bili-
rubin. Also, volume contraction may lead to increased serum albumin con-
centration, which will shift bilirubin from the tissues into the circulation, 
producing the opposite effect. With that said, assess for jaundice in any 
patient in whom there is a suspicion for liver disease. In addition, examine 
the skin for other sequelae of liver disease such as telangiectasias, gyneco-
mastia, or caput medusa. The abdominal examination is also helpful in eva-
luating the patient with jaundice. Ascites is often present with acute or chronic 
liver disease. Rapid onset of ascites and hepatomegaly is concerning for 
portal vein thrombosis (Budd-Chiari syndrome) whereas ascites with abdo-
minal tenderness is suspicious for spontaneous bacterial peritonitis. A tender 
liver margin can be indicative of hepatic congestion from cholestasis or con-
gestive heart failure or can be indicative of inflammation from hepato-
cellular injury. The liver can either be enlarged (as in the case of hepatitis) 
or non-palpable (as in the case of cirrhosis). A Murphy's sign on examination 
can indicate acute cholecystitis. Auscultation of the lungs can reveal pleural 
effusion or pulmonary edema secondary to CHF, sepsis-associated acute lung 
injury, or end-stage liver disease. Perform a careful cardiovascular exami-
nation, looking for signs of right heart failure such as jugular venous disten-
sion, hepato-jugular reflux, and lower extremity edema. Hepato-jugular 
reflux occurs when gentle pressure over the patient’s right upper quadrant 
produces elevation in the jugular venous pressure. Right heart failure is 
caused by left heart failure or pulmonary hypertension. The right heart expe-
riences elevated filling pressures leading to volume overload in the right-sided 
circulation including hepatic congestion. Perform a neurological exami-
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nation to assess the patient’s mental status including level of consciousness, 
orientation, and cognitive function. In addition, assess the patient for the pre-
sence of asterixis, a handflapping tremor. It is induced by having patients 
extend their arms and dorsiflex their wrists. If Wilson's disease is a consi-
deration, a slit lamp examination can be performed to evaluate for a Kayser-
Fleischer ring: a green to red pigment on the outer aspect of the cornea. 
Laboratory diagnostic studies 
The diagnostic tests ordered in the ED will vary greatly depending 
on how ill the patient appears as well as the likely causes of the jaundice. 
A wellappearing neonate may only require a total serum bilirubin measu-
rement whereas a septic patient thought to be in fulminant liver failure will 
need comprehensive metabolic testing and imaging.  
Liver function panel 
At a minimum, any patient presenting to the ED with jaundice should 
have a serum bilirubin with quantification of the conjugated (direct) and un-
conjugated (indirect) fractions. The value in fractionating the bilirubin is to de-
termine whether the jaundice is being caused by hepatic dysfunction. The total 
bilirubin concentration is not a sensitive indicator of hepatic dysfunction 
due to the liver's reserve capacity for metabolizing bilirubin. Elevated indirect 
bilirubin comes from conditions that cause either an overproduction of bili-
rubin or impaired hepatic uptake and conjugation. An elevated direct bili-
rubin fraction suggests a defect in hepatic excretion and is a more sensitive 
indicator of hepatic disease. In general, the normal values for indirect and 
direct bilirubin are less than 1.2 mg/dL and less than 0.3 mg/dL, respectively. 
Fractionated bilirubin is not useful in differentiating hepatocellular injury 
from cholestasis. The remainder of the hepatic panel is needed for this. If there 
is high clinical suspicion for liver disease, the aminotransferases, alkaline 
phosphatase (AP), albumin time, and prothrombin time should be evaluated. 
If these values are all normal, consider hemolysis or inherited disorders as 
the cause for jaundice. Gilbert's syndrome or Crigler-Najjar syndrome cause 
isolated unconjugated hyperbilirubinemia, and the Dubin-Johnson and Rotor 
syndromes cause isolated conjugated hyperbilirubinemia. Alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) are two liver enzymes 
commonly used as markers of hepatocellular injury. A small fraction of asymp-
tomatic patients can also have slight elevations. The absolute number of the 
elevation is not specific for a particular cause of injury; however, there is some 
clinical utility of the ratio of the two enzymes. An AST/ALT ratio of 2:1 sug-
gests alcoholic liver disease. Elevations of alkaline phosphatase and bilirubin 
relative to the aminotransferases suggest intrahepatic or extrahepatic chole-
stasis. Alkaline phosphatase is also derived from bone, kidney, or placenta 
in the first trimester and can be elevated in diseases affecting those tissues 
as well. Correlation of elevated AP with elevations in either serum gamma-
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glutamyl transpeptidase (GGT) or 5'-nucleotidase points to a hepatic source 
of AP. Both enzymes are secreted by bile canaliculi and elevations are sen-
sitive for hepatobiliary disease. A normal 5'-nucleotidase does not rule this 
out, however.  
Chemistry panel 
The basic chemistry panel, including electrolytes and renal function, 
will not help narrow the differential diagnosis of jaundice. It will, however, 
aid in disposition because it will give further insight into the degree of illness. 
Jaundiced patients can have a depressed renal function from dehydration or 
sepsis. In severe liver disease, anuric renal failure can develop – also termed 
the hepatorenal syndrome. Patients with fulminant liver failure or sepsis can 
have disorders in acid/base homeostasis. This will be seen as a decreased bicar-
bonate concentration or an increased anion gap.  
Complete blood count 
A complete blood count (CBC) will not necessarily help to determine 
the etiology of jaundice but can aid in disposition. Patients with a white 
blood cell count (WBC) higher than 12,000 or below 4 000 or greater than 
10 % bands may have sepsis. Low hemoglobin and hematocrit can signify 
anemia from chronic disease, hemolysis, or hemorrhage. A reticulocyte count 
and RBC indices will help in differentiation. A reticulocyte index of less than 
2 % favors underproduction states such as anemia of chronic disease or iron, B12, 
or folate deficiencies. Values greater than 2 % favor RBC loss or destruction, 
as in hemorrhage or hemolysis. Thrombocytopenia may be present due to 
chronic disease, infection, or medications. 
Coagulation studies 
The liver produces all factors in the clotting cascade with the exception 
of factor VIII and von Willebrand factor (vWF), which are produced by the vas-
cular endothelium. As the liver begins to fail and the serum concentration 
of these proteins falls, the prothrombin time (PT) and the international normali-
zation ratio (INR) will rise. This is a particularly serious finding as it indicates 
significant hepatic dysfunction. An elevated PT and partial thromboplastin time 
(PTT) can also be indicative of disseminated intravascular coagulation (DIC). 
Other tests 
Lactic acid levels can aid in the evaluation of tissue perfusion in the set-
ting of shock. In the setting of liver failure from acetaminophen overdose, 
arterial lactate may have efficacy in helping to identify patients who will require 
liver transplantation. More specific tests can be sent based on the differential 
diagnosis generated by the history, physical examination, and liver panel. 
If hemolysis is suggested, consider sending a peripheral smear, Coomb's test, 
lactate dehydrogenase (LDH), and haptoglobin. An elevated LDH and de-
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creased haptoglobin can help quantify the hemolysis. The peripheral smear 
can show the cause of the hemolysis such as spherocytes or sickle cells. A sum-
mary of peripheral smear findings can be found in table 9. If hepatocellular 
injury is suspected, other tests include acetaminophen (APAP) level and viral 
hepatitis serologies. 
 
Table 10  
Peripheral smear findings 
 Diagnosis 
Spherocytes Hereditary spherocytosis, drug-induced 
hemolysis, autoimmune 
Bite cells/Heinz bodies G-6PD 
Sickle cells Sickle cell disease 
Schistocytes Microangiopathic hemolytic anemia 
 
Determine an APAP level for any patient in whom there is any suspicion 
for ingestion or for whom the hepatocellular injury is undifferentiated. Treat-
ment with Nacetylcysteine (NAC) is indicated for any value above the treat-
ment line on the nomogram. Acute hepatitis can be caused by hepatitis A (HAV), 
hepatitis B (HBV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-
Zoster virus (VZV), and herpes simplex virus (HSV). Hepatitis B and C can 
also cause chronic hepatitis leading to hepatic fibrosis, cirrhosis, or hepato-
cellular carcinoma. Appropriate serologies are summarized in table 10.  
 
Table 10 
Hepatitis serologies 
Hepatitis A Anti-HAV IgM 
Hepatitis B Anti-HBc antibodies: (+) IgM for acute infection,  
(+) IgG for previous or ongoing infection  
HBsAg 
Anti-HBs: resolution or immunity 
HBeAg: increased viral replication 
Anti-HBe: waning viral replication 
Hepatitis C Anti-HCV 
HCV RNA 
Hepatitis D Anti-HDV 
Hepatitis E IgM anti-HEV 
Other viruses CMV, VZV, EBV, HSV 
 
There are additional tests for less frequent causes of hepatic dysfunction 
such as autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, 
Wilson's disease, and alpha-1-antitrypsin deficiency. Detection of these conditions 
is often outside the scope of emergency medicine; however, the work-up 
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can be initiated in the ED in consultation with the patient's primary physician 
or the admitting hospitalist. These tests are summarized in table 11. 
 
Table 11 
Miscellaneous tests 
Autoimmune hepatitis 
Anti-smooth muscle antibodies (ASMA) 
Antinuclear antibody (ANA) 
Anti-liver/kidney microsome type 1 (anti-LKM1) 
Anti-soluble liver antigen (anti-SLA) 
Hemochromatosis Iron saturation, ferritin 
Wilson's disease Urinary copper, ceruloplasmin 
Alpha-1 antitrypsin deficiency Serum protein electrophoresis 
Primary biliary cirrhosis Anti-mitochondrial antibodies 
Primary sclerosing cholangitis p-ANCA 
 
Radiology diagnostic studies 
Imaging is indicated to differentiate between intraand extrahepatic 
etiologies of obstructive jaundice. For patients in whom there is concern for ob-
structive jaundice, the most commonly employed tests in the ED are 
ultrasound (US), computed tomography (CT), and hepatobiliary 99mTc-imino-
diacetic acid (HIDA) scans. Other imaging modalities require more time, se-
dation, or specialist training. They include magnetic resonance imaging (MRI), 
endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance 
cholangiopancreatography (MRCP), and percutaneous transhepatic cholangio-
graphy (PTC). These are outside the scope of usual EM practice, but can be 
discussed with the appropriate consultants.  
Ultrasound 
The chief advantages are that it is the least expensive and invasive imaging 
technique available. In addition, it allows for the evaluation of adjacent struc-
tures such as the kidney and aorta. It can detect calculi in the gallbladder 
with 98 % sensitivity and 93.5–97.7 % specificity. It can detect the presence 
of obstruction with a sensitivity and specificity as high as 91 and 95 %, 
respectively. A dilated common bile duct (CBD) (greater than 5 mm) is diag-
nostic of extrahepatic obstruction. The only caveat is post cholecystectomy 
and liver transplant patients, who may have a slightly dilated common duct 
without obstruction. Sensitivity is lower (75 %) for detecting choledocho-
lithiasis, partly due to overlying duodenal gas. Serial hepatic Doppler ultra-
sounds of patients with acute liver failure have shown that hepatic artery resistive 
index (HARI) is significantly higher for patients who fulfill transplant 
criteria, suggesting that this can be used as a diagnostic tool in patients who 
are transplant candidates. HARI has been previously evaluated in patients 
with liver transplants and cirrhosis.  
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Computed tomography (CT) 
Contrasted CT of the abdomen has been shown to have similar sen-
sitivity to 75 % in finding common bile duct stones. A small stone may be 
missed by thick cuts, and non-calcified stones may not be visualized at all. 
The chief advantage of CT over US is that other organs can be evaluated via CT. 
In the setting of acute liver failure, liver volume less than 1 000 mL on CT 
or hepatic necrosis greater than 50 % is associated with poor prognosis. 
Other advantages include that CT is often available at all hours in most hos-
pitals. Other disadvantages include cost and the need to administer iodinated 
radiocontrast dye, which is contraindicated in patients with dye allergies or 
renal insufficiency. 
Hepatobiliary iminodiacetic acid (HIDA) 
HIDA is a valuable tool in the detection of biliary obstruction. Its utility 
lies primarily in the detection of cholelithiasis or cholecystitis. HIDA may 
be useful in the case of equivocal US. Disadvantages are that it is of limited 
value in patients with nonfunctioning gallbladders due to prolonged fasting 
or severe hepatic dysfunction. Also, it may not be available at all hours. 
Endoscopic retrograde cholangiopancreatography (ERCP) 
ERCP is an invasive procedure that allows for the direct visualization 
of the biliary tree and pancreatic ducts. For this reason, it is superior to CT 
or US for detection of site and cause of extrahepatic obstructions. Its main 
advantage is that there are many therapeutic and diagnostic options available. 
Common duct stones can be removed and stents placed if necessary. Tissue 
diagnosis can be obtained through brush biopsy or fine needle aspiration. In ad-
dition, endoscopic drainage can be performed for patients with malignant 
causes of obstruction. ERCP also allows for the use of endoscopic ultrasound 
(EUS). EUS is more invasive than transabdominal US or CT but allows for 
greater sensitivity in detecting pancreatic tumors and small common duct 
stones. The primary disadvantages of EUS are that it does not allow for the 
removal of the stones and it is not available in many institutions.  
Magnetic resonance cholangiopancreatography (MRCP) 
MRCP is the most sensitive of the non-invasive methods for dete-
cting ductal calculi. In the presence of dilated ducts, sensitivity and specificity 
have been reported to be 90–100 %. Stones greater than 4 mm are readily seen 
as filling defects but cannot be differentiated from other filling defects such 
as blood clots, tumor, sludge, or parasites. It is a useful technique in the setting 
of failed ERCP or as an alternative to ECRP in the evaluation of choledo-
cholithiasis hilar obstruction from ductal tumor or periductal compression. 
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Percutaneous transhepatic cholangiography (PTC) 
PTC is an invasive procedure in which a needle is passed through the 
skin into the hepatic parenchyma and advanced into a peripheral bile duct. 
Contrast media is used to provide an image of the biliary tree. The sensitivity 
and specificity are nearly 100 % for diagnosing biliary tract obstruction. 
Major complications are 3–5 % and it is more expensive than CT or US. 
Choice of imaging procedure 
Of the aforementioned imaging modalities, CT and US are the two that 
are usually available. The diagnostic approach depends on the pre-test proba-
bility that the cause is obstructive rather than non obstructive as well as the 
pre-test probability that the obstruction is malignant versus benign. In cases 
in which clinical suspicion for malignant obstruction is high, CT is probably 
the best screening study. Not only can CT identify the site of the obstruction, 
but it is also 70 % accurate in staging and determining resectable versus 
unresectable disease. If the patient has a contraindication to IV dye such as 
a dye allergy or renal insufficiency, an ultrasound can be done to confirm 
the obstruction; the patient can then undergo MRI and/or MRCP for staging 
at a later date. If ultrasound is not available or there is clinical concern about 
other abdominal organs, a non-contrast abdominal CT may provide some infor-
mation but will not be as sensitive as a contrast study. Patients with a high 
likelihood for benign obstruction, such as those with gallstones, usually present 
with acute onset of jaundice and abdominal pain. They may have a previous 
history of gallstones or biliary surgery. These patients are best screened with US 
because it is accurate, inexpensive, and noninvasive. The risk is that some 
common duct stones may not be visualized. If a common duct stone is iden-
tified or highly suspected based on the ultrasound, ERCP is indicated for re-
moval. If the ultrasound is equivocal, consider HIDA scan, contrast CT, or con-
sulting gastroenterology or general surgery for ERCP. Patients with prior 
biliary surgeries or suspected sclerosing cholangitis in whom biliary stricture 
is a diagnostic consideration should undergo MRCP to avoid the possibility 
of ERCP – associated ascending cholangitis. In patients with a low clinical 
likelihood for mechanical obstruction, the recommendations for initial imaging 
modalities are mixed. The American College of Radiology's (ACR's) appro-
priateness criteria for the jaundiced patient recommends starting with US32 
whereas other sources recommend contrasted CT. The advantage of CT in this 
case is that it allows for the evaluation of the other abdominal structures, spe-
cifically the liver parenchyma, portal vein, inferior vena cava (IVC), and intra-
hepatic bile canicular system. If the imaging is negative for extrahepatic 
obstruction, further work-up will need to be done to assess for causes of intra-
hepatic cholestasis. Similarly, in patients with intermediate pre-test proba-
bility for obstruction, the initial choice of imaging depends on the dominant 
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clinical symptom. US is recommended if the sole question is whether or not ob-
structions exists. CT may be better if there is a need to assess other abdominal 
organs. Some patients may require both tests as, in many ways, the tests are 
complementary in providing diagnostic information that is of major impor-
tance in the initial work up of patients presenting with acute jaundice. 
Patients with inconclusive imaging can be referred for EUS, ERCP, or MRCP.  
Treatment 
Treatment will depend largely on the likely clinical entity causing 
the jaundice. Treatment is largely supportive; however, there are a few instances 
in which specific therapy must be initiated. 
Hemolysis 
In patients with massive hemolysis, treatment also depends on the cause 
of the hemolysis. Consider transfusion for patients with low hemoglobin/he-
matocrit or for those who continue to be symptomatic despite other therapeutic 
measures. Refer patients with hereditary spherocytosis for splenectomy. 
Those with glucose-6-phosphatase dehydrogenase deficiency or drug-induced 
hemolytic anemia should avoid the offending agent. Treat warm and cold 
agglutinins with corticosteroids. Patients with sickle cell crises should receive 
hydroxyurea, hydration, supplemental oxygen, and analgesia. Patients with 
thrombotic thrombocytopenic purpura/hemolytic uremic syndrome require 
plasma exchange and glucocorticoids. Patients with disseminated intravascular 
coagulopathy (DIC) are very ill and require massive amounts of blood pro-
ducts (packed red blood cells [PRBCs], fresh frozen plasma [FFP], platelets, 
and cryoprecipitate) in order to replete the missing elements of the coagu-
lation cascade.  
Extrahepatic obstruction 
If the labs and imaging point to an obstructive picture, ascending 
cholangitis must be ruled out. Patients with ascending cholangitis must be ma-
naged expeditiously as they can develop septic shock at any time. Start all 
patients with this diagnosis on empiric antibiotics to cover gramnegatives 
and Enterococcus. Obtain surgical consultation early in patients presenting 
with sepsis and evidence of organ dysfunction, as they should have drainage 
established emergently via ERCP or cholecystostomy if they are unstable. 
Patients who are not septic at presentation can have a course of antibiotics 
and have drainage performed at a later time. Acute drainage is indicated for 
any patient who has persistent abdominal pain or develops sepsis. Patients 
should also be given IV hydration and adequate analgesia. Patients with extra-
hepatic obstructive jaundice without cholangitis require drainage. For benign 
obstructions such as gallstones or strictures, ERCP is indicated for stone 
removal. Patients with obstructive jaundice due to malignancy also benefit 
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from biliary decompression whether operative, endoscopic, or palliative. Once 
jaundice develops, the malignancies are associated with more advanced disease 
and increased morbidity and mortality. Patients with biliary obstruction are 
also at increased risk of infection due to poor neutrophil function. Obstructive 
jaundice is associated with altered fluid and electrolyte homeostasis that can 
result in dehydration and renal dysfunction. Biliary drainage has been shown 
to improve cardiac function and, not insignificantly, food intake. Preoperative 
drainage has not been shown to be beneficial in patients with obstructive 
jaundice secondary to malignancy who are undergoing surgery. Palliative 
biliary drainage is recommended for patients who are not surgical candidates. 
Endoscopic drainage with biliary stenting has been found to have fewer 
complications, though there is a higher rate of recurrent obstruction. For this 
reason, a surgical consultation should be obtained on all patients presenting 
to the ED with extrahepatic obstructive jaundice.  
Hepatocellular injury 
Patients with jaundice and transaminases out of proportion to elevation 
of AP have a hepatocellular injury pattern. It is essential that acute liver failure 
be ruled out in these patients. The diagnosis can be made if there is evi-
dence of coagulopathy or altered mental status. The early signs of hepatic 
encephalopathy can be difficult to detect. It may be necessary to contact family 
members or the patient's nursing home and ask about sleep disturbances, 
agitation, and disorientation. Hepatic encephalopathy in acute liver failure 
initially presents as agitation, delusions, and hyperkinesias and can precede 
the development of jaundice. Unlike encephalopathy associated with chronic 
liver disease, it is relatively common but it progresses rapidly to deeper 
levels of ostentation and coma. As mentioned previously, coagulopathy can 
develop as the serum concentrations of factors II, V, VII, IX, and X fall. Fresh-
frozen plasma (FFP) is recommended for any patient with active bleeding or 
prior to invasive procedures such as central lines or ICP monitors. It has not 
been shown to be beneficial in the absence of active bleeding. Patients with 
acute liver failure also have abnormal platelet function and thrombocyto-
penia. Platelet transfusion may be necessary for patients with counts below 
20,000 per cubic millimeter. Patients with acute liver failure can also present 
with or develop circulatory collapse resembling septic shock. Hypotension 
develops as a result of hypovolemia, greatly decreased systemic vascular 
resistance, and increased interstitial edema. Approximately half of all patients 
with advanced hepatic failure will develop oliguric renal failure. Tissue hypo-
perfusion leads to diminished tissue oxygen extraction, anaerobic metabolism, 
and lactic acidosis. Patients should be supported with intravenous crystal-
loids to keep MAP >65 and urine output >0.5 mL/kg/hr. Patients who are 
still hypotensive (MAP <65) despite volume resuscitation should receive 
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inotropic support with dopamine or norepinephrine. Patients with acute liver 
failure are prone to hypoglycemia due to increased metabolic activity. Blood 
glucose should be closely monitored while in the ED, and abnormalities 
should be treated with intravenous glucose or insulin. Lastly, these patients 
are at increased risk of infection due to reduced immune response, multiple 
indwelling foreign bodies, and systemic steroids or H2 blockers. Broad-
spectrum antibiotics can be initiated in the ED if the patient is febrile, has ele-
vated WBCs, a bandemia, or a documented source of infection; outside of this, 
prophylactic antibiotics are not recommended and may select for resistant 
organisms. The definitive treatment for many patients with fulminant liver 
failure is transplantation. All patients presenting with acute liver failure 
should be considered for transfer to the closest facility with transplantation 
capabilities. Patients are candidates for transplant if they have normal function 
in other organs (e.g., brain and kidney) and if the disease is not likely to recur 
in the graft. The decision to transfer the patient to a transplant center should 
be made in conjunction with the transplant surgeon and should be consi-
dered as soon as the diagnosis of ALF is made.  
Acetaminophen-induced liver injury 
Acetaminophen-induced liver injury is one of the few scenarios in which 
the EP can intervene positively and potentially prevent the development 
of acute liver failure and the need for liver transplant. Treatment for acetamino-
phen-induced liver toxicity is N-acetylcysteine (NAC). The dose of NAC is 
a 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 additional 
doses. 92 If given within eight hours of ingestion, NAC is 100 % protective 
from liver injury. It has also been shown to be beneficial if given after that 
time. Unfortunately, clinical signs of hepatotoxicity do not usually develop 
until the second or third day post-ingestion, when NAC is of questionable 
benefit. The American College of Emergency Physicians (ACEP) recommends 
administering NAC to patients with suspected acetaminophen overdose who 
are unable to be risk stratified by the Rumack-Matthew nomogram. Intra-
venous NAC is FDA-approved for acetaminophen overdose if given within 
eight hours of ingestion. The dose is 150 mg/kg IV over 60 minutes, then 
50 mg/kg over 4 hours, then 100 mg/kg over 16 hours. Advantages to this 
approach are shorter duration of therapy and no reduction in bioavailability 
of oral NAC due to charcoal administration or vomiting. It has been shown 
to be as safe and effective as oral NAC. Activated charcoal should be consi-
dered for acute ingestions if there are no contraindications. Further therapies 
should be coordinated with the local poison control center. Consider ICU 
admission or transfer to the nearest transplant center for wellappearing 
patients with moderately elevated INR or transaminases as they will require 
close monitoring. 
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Other causes of hepatocellular injury 
Once acute liver failure and acetaminophen toxicity have been ruled out, 
treatment of patients with hepatocellular injury generally involves treatment 
of symptoms such as pain and nausea. Patients ith autoimmune hepatitis benefit 
from early administration of prednisone. Although there is no specific level 
of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that 
has been shown in the literature to mandate admission, patients with fever, 
coagulopathy, altered mental status, or intractable pain should be hospita-
lized.  
Key points for jaundice 
• All patients require a thorough history (including medications, drug 
and alcohol use, family history, and travel history) and a careful physical 
examination for the manifestations of liver disease. 
• Check at least a total and direct bilirubin level on all patients. Most 
patients will also need a chemistry panel with liver function tests, a CBC 
with differential, and a PT/INR. 
• Patients with jaundice and anemia due to massive hemolysis or 
dyserythropoiesis require admission. 
• Patients with elevated alkaline phosphatase and gamma-glutamyl-
transferase likely have a biliary tract obstruction. They should get an imaging 
procedure in the ED (CT or US) and have a surgical or gastrointestinal consult, 
depending on the findings. 
• Patients with primarily elevated aminotransferases (AST and ALT) 
have hepatocellular injury. They should be admitted if there is evidence 
of coagulopathy, sepsis, mental status changes, intractable pain, or nausea. 
• Patients with the triad of hepatocellular injury, coagulopathy, and 
mental status changes have acute liver failure. They should be admitted 
to an ICU or transferred to the nearest liver transplant center. 
• Any pregnant patient with jaundice should be managed in conjun-
ction with the obstetrician. Patients who present with jaundice in the third 
trimester may require delivery and may need to be transferred to a center 
with high-risk obstetric and neonatal facilities.  
• Well-appearing neonates with a serum bilirubin below 15 mg/dL 
can be discharged home with close follow-up. 
• NAC is 100 % hepatoprotective if given within eight hours of acute 
acetaminophen ingestion; it may also be of benefit in late or chronic ingestions, 
and poison center consultation is recommended. 
Summary 
Jaundice is an infrequent complaint to the ED, but its presence on phy-
sical examination can indicate significant hepatic or hematologic pathology. 
The broad differential diagnosis spans the breadth of emergency medicine 
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from medical to surgical causes with special consideration to the pediatric 
and adult patients. All of this requires the EP to be an astute diagnostician 
by obtaining a detailed history and performing a thorough physical exami-
nation. In addition, some patients will require resuscitation and stabilization 
while in the ED for sepsis or acute liver failure. In cases such as acetaminophen 
overdose, prompt treatment can potentially save the patient’s life. Finally, 
appropriate use of consultants and consideration of transfer can aid in the diag-
nosis and treatment of your patients.  
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